Elutia Welcomes Major Research Breakthrough
EluPro successfully eliminated bacteria typically associated with infections related to cardiac implants in a well-established preclinical infection model.
SILVER SPRING, Md. — Elutia Inc. (NASDAQ: ELUT) has excitedly announced some important news regarding its antibiotic-eluting biologic product, EluPro. This product is the first of its kind, fully approved by the FDA, and it has demonstrated impressive capabilities in fighting bacterial contamination linked to Cardiovascular Implantable Electronic Devices (CIEDs).
Promising Results from Preclinical Research
New findings published in Frontiers in Drug Delivery have shown encouraging results from preclinical studies that used an animal model. EluPro proved to be highly effective at reducing bacterial colonization while keeping systemic antibiotic exposure minimal.
Achieving FDA Approval
By mid-2024, EluPro received FDA clearance for use with CIEDs. Its approval has now expanded to include additional devices that support pain management, epilepsy, incontinence, and sleep apnea. The very first patient implant using EluPro was carried out successfully in September 2024.
Expert Opinions on EluPro’s Potential
Dr. M. Rizwan Sohail from Baylor College of Medicine, who played a key role in the research, shared his thoughts on EluPro’s significance. “This biologic envelope not only boosts implant stability and reduces device migration but also tackles the risks of bacterial contamination, a major concern in CIED procedures.” He emphasized that recent clinical findings also indicate that EluPro may help lessen scarring and fibrosis around implants, which could simplify reoperation processes.
Details of the Preclinical Study
The studies utilized a rabbit model to simulate CIED infections. Implants were inserted either with EluPro or a non-antibiotic control envelope, followed by exposure to various bacterial species. Over a period of one week, the sites of the implants were closely monitored for any signs of infection and bacteria. The results were clear—none of the subjects treated with EluPro showed signs of infection, in stark contrast to the control group, which experienced fevers and needed extra medical attention.
EluPro: Advancing Infection Control
“These results strongly validate EluPro’s potential to enhance infection control during CIED procedures,” stated Dr. Michelle LeRoux Williams, Elutia's Chief Scientific Officer. “As the first biologic antibiotic-eluting envelope to receive FDA clearance, EluPro is set to transform the protection of implantable devices. Following the accomplishment of the initial human implant, we are preparing for EluPro's commercial launch scheduled for January 2025.”
Commitment to Ongoing Innovation
Elutia’s mission goes beyond merely creating advanced products; the company strives to create a future where patients have access to safer, more efficient implantable technologies. They continue to push forward with innovations, ensuring medical devices meet patient needs for optimal compatibility and effectiveness.
About Elutia
Elutia is dedicated to the development and commercialization of drug-eluting biomatrix products that enhance compatibility between medical devices and patients. With a vision to transform healthcare into a more patient-focused model, Elutia is committed to personalizing medicine, enabling patients to thrive and live their lives freely.
Frequently Asked Questions
What is EluPro?
EluPro is an antibiotic-eluting biologic envelope created to prevent infections related to implantable medical devices.
Why is the new study significant?
This study provides compelling evidence that EluPro effectively decreases bacterial colonization while keeping antibiotic exposure low, which is crucial for enhancing patient safety.
What types of devices can use EluPro?
EluPro has FDA approval for use with CIEDs, as well as for neuromodulators and neurostimulators for managing conditions like pain and epilepsy.
When is EluPro’s commercial launch planned?
Elutia intends to launch EluPro commercially in January 2025, following the successful initial human implants.
Who is involved in EluPro's research?
Research contributions come from experts such as Dr. M. Rizwan Sohail of Baylor College of Medicine, alongside Elutia’s dedicated scientific team led by Dr. Michelle LeRoux Williams.
